Abstract
Serum levels of β2-microglobulin (S-B2m) were analysed at diagnosis in 69 cases of acute myeloid leukemias (AML) as a possible prognostic indicator. S-B2m was correlated to various clinical and laboratory features and with respect to response to chemotherapy and following clinical outcome. SB2m was found to be increased >3mg/l) in 40.6% of tested patients and, in particular, in the monocytic variants (M4, M5) of AML (4.2 versus 2.3mg/l, p3mg/l and white blood cell count >20x109/l were independent variables significantly influencing disease-free survival in responsive patients (five years DFS for S-B2m > or
Original language | English |
---|---|
Pages (from-to) | 1076-1078 |
Number of pages | 3 |
Journal | Leukemia |
Volume | 6 |
Issue number | 10 |
Publication status | Published - 1992 |
ASJC Scopus subject areas
- Cancer Research
- Hematology